Skip to main content
TipRanks
Go Ultimate75% OFF

Regenerative Medical Technology Group (RMTG) AI Stock Analysis

6 Followers
RMTG

Regenerative Medical Technology Group

(Other OTC:RMTG)

Select Model
Rating:43Neutral
Price Target:$0.03â–¼(-3.33% Downside)
Action:reiterated
Date:11/04/26

The score is primarily constrained by high financial risk (negative equity, sizable debt relative to assets, ongoing net losses and negative free cash flow) and weak technical momentum (trading below key moving averages with negative MACD and very low RSI). Strong revenue growth and positive corporate messaging around scaling and deleveraging provide some support, but not enough to offset balance-sheet strain and downtrend signals.

Positive Factors
Strong Revenue GrowthRapid revenue expansion demonstrates meaningful demand for the company’s regenerative medicine offerings and provides a larger base over which fixed costs can be absorbed. If sustained, this momentum could improve operating leverage and support broader market development.
Negative Factors
Stressed Balance SheetNegative equity and debt that is large relative to assets leave the company with little financial cushion for creditors or shareholders. This stressed capital structure can constrain investment, increase dependence on financing, and make balance-sheet repair a multi-quarter priority.

Regenerative Medical Technology Group (RMTG) vs. SPDR S&P 500 ETF (SPY)

-75%-50%-25%0%25%50%75%100%125%RMTG-49.15%SPY+14.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$412.17K
Dividend Yield
―
Average Volume (3M)
57.52K
Price to Earnings (P/E)
-0.0
Beta (1Y)
-1.53
Revenue Growth
94.32%
EPS Growth
-158.38%
Country
US
Employees
1
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Regenerative Medical Technology Group Business Overview & Revenue Model

Company Description

Regenerative Medical Technology Group Inc. operates in the regenerative medicine industry in the United States and internationally. It provides products, solutions, equipment, services, and training to doctors and their staff in the application of st...

Regenerative Medical Technology Group Financial Statement Overview

Summary

Revenue growth is strong (TTM up ~47.7%) with solid gross margin (~59.8%) and improved operating results (small positive EBIT). However, the company remains deeply unprofitable (TTM net margin around -101%), has negative equity (about -$39.3M) alongside sizeable debt (~$21.7M) versus a small asset base, and free cash flow is still negative—together indicating elevated financial and funding risk.

Income Statement

34Negative

Balance Sheet

18Very Negative

Cash Flow

28Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue9.41M5.10M4.11M2.41M1.53M437.89K
Gross Profit5.51M2.81M2.82M1.68M876.97K150.14K
EBITDA2.00M-83.56K301.74K-3.01M-1.02M-10.11M
Net Income-9.53M-7.81M-5.56M-9.81M-5.49M-12.88M
Balance Sheet
Total Assets5.85M4.49M3.82M2.88M8.08M9.31M
Cash, Cash Equivalents and Short-Term Investments1.32M956.72K1.17M530.54K1.65M2.98M
Total Debt21.74M19.57M20.05M17.65M15.14M13.37M
Total Liabilities45.11M39.23M31.18M24.67M20.06M16.06M
Stockholders Equity-39.26M-34.75M-27.36M-21.80M-11.98M-6.76M
Cash Flow
Free Cash Flow-582.33K-1.31M635.28K-804.80K-1.31M-9.88M
Operating Cash Flow268.56K-706.52K850.70K-419.20K-1.11M-9.88M
Investing Cash Flow-850.89K-602.58K-215.42K-385.60K-198.43K666.47K
Financing Cash Flow291.38K1.10M0-309.85K-20.78K12.15M

Regenerative Medical Technology Group Technical Analysis

Technical Analysis SentimentNegative
Last Price0.03

Price Trends

50DMA0.05Negative
100DMA0.06Negative
200DMA0.05Negative

Market Momentum

MACD-0.01Negative
RSI25.28Positive
STOCH30.16Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RMTG, the sentiment is Negative. The current price of 0.03 is below the 20-day moving average (MA) of 0.03, below the 50-day MA of 0.05, and below the 200-day MA of 0.05, indicating a bearish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 25.28 is Positive, neither overbought nor oversold. The STOCH value of 30.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RMTG.

Regenerative Medical Technology Group Risk Analysis

Regenerative Medical Technology Group disclosed 37 risk factors in its most recent earnings report. Regenerative Medical Technology Group reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.Because the company is a "smaller reporting company," we may take advantage of certain scaled disclosures available to us, resulting in holders of our securities receiving less company information than they would receive from a public company that is not a smaller reporting company.Q4, 2023
2.Because we are a small company with a limited operating history, holders of common stock may find it difficult to sell their stock in the public markets.Q4, 2023
3.Our common stock is quoted through the otc markets, which may have an unfavorable impact on our stock price and liquidity.Q4, 2023

Regenerative Medical Technology Group Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

RMTG against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
BJDXBJDX44Neutral$2.92M-0.11-113.80%――95.46%
WOKWOK43Neutral$5.36M-0.01-18.55%―――
RMTGRMTG43Neutral$412.17K-0.0427.29%―94.32%-158.38%
IVFIVF42Neutral$3.10M-0.02-47.41%―13.76%99.18%

* Healthcare Sector Average

Performance Comparison

-100%-50%0%50%100%RMTGBBLGIVFBJDXNIVFWOKDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
RMTG and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
RMTGRegenerative Medical Technology Group Inc.0.03-0.03-49.15%
BBLGBone Biologics Corp0.33-1.30-80.06%
IVFInvo Fertility Inc2.60-70.68-96.45%
BJDXBluejay Diagnostics, Inc.2.61-20.27-88.59%
NIVFNewgenivf Group Limited0.23-6073.69-100.00%
WOKWORK Medical Technology Group LTD1.20-40898.80-100.00%

Regenerative Medical Technology Group Corporate Events

Business Operations and StrategyDelistings and Listing ChangesFinancial DisclosuresShareholder Meetings

Regenerative Medical Technology Group Highlights Growth, Financing Strategy

Positive
Aug 25, 2026

On August 20, 2026, Regenerative Medical Technology Group held a previously announced investor video call in which management addressed shareholder questions about growth, financing, and strategic direction. Executives highlighted strong revenue mome...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 04, 2026